Strive CEO Matt Cole warned that artificial intelligence is significantly increasing the risks associated with Bitcoin self-custody, meaning that holders who secure their own coins face greater challenges. He emphasized that self-custody is more complex than many realize and requires ongoing effort to maintain security. Cole's comments highlight the growing need for vigilance as AI technologies evolve, potentially exposing Bitcoin holders to new vulnerabilities. Meanwhile, Strive has been expanding its Bitcoin treasury, recently increasing its holdings to 36,818 BTC after additional purchases in mid-October.
Strive CEO Matt Cole's warning about AI raising Bitcoin self-custody risks is presented here with Pluang's cryptocurrency market context as of Nov 09, 2026 16:01 WIB. Of 50 major cryptocurrencies priced on Pluang, 6 rose and 43 fell today. Notable movers include SXP (Solar) down 46.27% at Rp37, ONE (Harmony) down 27.43% at Rp28 with a typical hold time of 153 days and a 51% sell order activity, and BAL (Balancer) up 11.14% at Rp16,297.
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to redistribute excess cash to shareholders and reduce share capital. As of early November 2026, the company has repurchased approximately 7.69 million shares ...
AL Sydbank A/S executed transactions to buy back 30,000 shares during week 45 as part of its ongoing share buyback program announced in February 2026, which totals DKK 1.1 billion. The program started in March 2026 and will conclude by January 2027, ...
AL Sydbank A/S continued its share buyback program in week 45, purchasing 30,000 shares at an average price of around 725 DKK, totaling approximately 21.76 million DKK. The buyback program, announced in February 2026 and running until January 2027, a...
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
